JPWO2022045336A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022045336A5 JPWO2022045336A5 JP2022545758A JP2022545758A JPWO2022045336A5 JP WO2022045336 A5 JPWO2022045336 A5 JP WO2022045336A5 JP 2022545758 A JP2022545758 A JP 2022545758A JP 2022545758 A JP2022545758 A JP 2022545758A JP WO2022045336 A5 JPWO2022045336 A5 JP WO2022045336A5
- Authority
- JP
- Japan
- Prior art keywords
- tandospirone
- pharma
- acceptable salt
- composition according
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 claims 41
- 229950000505 tandospirone Drugs 0.000 claims 41
- 239000000203 mixture Substances 0.000 claims 34
- 150000003839 salts Chemical class 0.000 claims 26
- 239000008280 blood Substances 0.000 claims 16
- 210000004369 blood Anatomy 0.000 claims 16
- 206010030312 On and off phenomenon Diseases 0.000 claims 10
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 8
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 8
- 229960004502 levodopa Drugs 0.000 claims 8
- 208000018737 Parkinson disease Diseases 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 5
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 229960003638 dopamine Drugs 0.000 claims 2
- 238000002651 drug therapy Methods 0.000 claims 2
- 230000000142 dyskinetic effect Effects 0.000 claims 2
- 239000002532 enzyme inhibitor Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000648 anti-parkinson Effects 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 210000001577 neostriatum Anatomy 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 230000000946 synaptic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020145967 | 2020-08-31 | ||
| PCT/JP2021/031722 WO2022045336A1 (ja) | 2020-08-31 | 2021-08-30 | パーキンソン病の運動合併症治療薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022045336A1 JPWO2022045336A1 (https=) | 2022-03-03 |
| JPWO2022045336A5 true JPWO2022045336A5 (https=) | 2024-09-04 |
Family
ID=80353469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022545758A Pending JPWO2022045336A1 (https=) | 2020-08-31 | 2021-08-30 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11628169B2 (https=) |
| EP (1) | EP4218764A4 (https=) |
| JP (1) | JPWO2022045336A1 (https=) |
| KR (1) | KR20230058615A (https=) |
| CN (1) | CN116113402A (https=) |
| AU (1) | AU2021332775A1 (https=) |
| CA (1) | CA3189670A1 (https=) |
| MX (1) | MX2023002422A (https=) |
| TW (1) | TW202227080A (https=) |
| WO (1) | WO2022045336A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116113402A (zh) * | 2020-08-31 | 2023-05-12 | 住友制药株式会社 | 帕金森病的运动并发症治疗药 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4507303A (en) | 1981-12-22 | 1985-03-26 | Sumitomo Chemical Company, Limited | Succinimide derivatives, compositions and method of use |
| JPS58126865A (ja) | 1981-12-22 | 1983-07-28 | Sumitomo Chem Co Ltd | 環状イミド誘導体及びその酸付加塩 |
| US5633009A (en) * | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
| JPH11228414A (ja) | 1998-02-06 | 1999-08-24 | Sumitomo Pharmaceut Co Ltd | タンドスピロン経皮剤 |
| JPH11228454A (ja) * | 1998-02-17 | 1999-08-24 | Sumitomo Chem Co Ltd | アルキニル置換アリールブロミド類の製造方法 |
| JP2002020291A (ja) | 2000-06-30 | 2002-01-23 | Sumitomo Pharmaceut Co Ltd | 認知機能障害の治療剤 |
| GB0027020D0 (en) * | 2000-11-03 | 2000-12-20 | Univ Manchester | Treatment of movement disorders |
| JPWO2005117886A1 (ja) | 2004-06-01 | 2008-04-03 | 久光製薬株式会社 | 貼付剤 |
| ATE413166T1 (de) | 2004-11-22 | 2008-11-15 | Hisamitsu Pharmaceutical Co | Transdermales pflaster enthaltend einen schmelzpunktsenkenden hilfsstoff |
| JP4873871B2 (ja) | 2005-02-28 | 2012-02-08 | 久光製薬株式会社 | 粘着剤及び貼付剤 |
| JP5243254B2 (ja) | 2006-10-11 | 2013-07-24 | 久光製薬株式会社 | 結晶含有貼付剤 |
| CA2839350A1 (en) | 2011-07-05 | 2013-01-10 | Contera Pharma Aps | The use of serotonin receptor agonists for treatment of movement disorders |
| CN104411301B (zh) | 2012-04-18 | 2018-02-06 | 康特拉医药公司 | 适于改善运动障碍治疗的口服药物配方 |
| KR20210107729A (ko) * | 2018-12-20 | 2021-09-01 | 콘테라 파르마 에이/에스 | 운동 장애의 치료 |
| JP2020145967A (ja) | 2019-03-13 | 2020-09-17 | 日清食品ホールディングス株式会社 | プライマー及び特定昆虫の検出方法 |
| US10758535B1 (en) | 2019-04-26 | 2020-09-01 | Sumitomo Dainippon Pharma Co., Ltd. | Therapeutic drug for dyskinesia |
| WO2021166987A1 (ja) | 2020-02-19 | 2021-08-26 | 大日本住友製薬株式会社 | 経皮吸収製剤 |
| CN116113402A (zh) * | 2020-08-31 | 2023-05-12 | 住友制药株式会社 | 帕金森病的运动并发症治疗药 |
-
2021
- 2021-08-30 CN CN202180053119.3A patent/CN116113402A/zh active Pending
- 2021-08-30 US US17/461,024 patent/US11628169B2/en active Active
- 2021-08-30 MX MX2023002422A patent/MX2023002422A/es unknown
- 2021-08-30 WO PCT/JP2021/031722 patent/WO2022045336A1/ja not_active Ceased
- 2021-08-30 KR KR1020237005487A patent/KR20230058615A/ko not_active Withdrawn
- 2021-08-30 CA CA3189670A patent/CA3189670A1/en active Pending
- 2021-08-30 JP JP2022545758A patent/JPWO2022045336A1/ja active Pending
- 2021-08-30 AU AU2021332775A patent/AU2021332775A1/en not_active Abandoned
- 2021-08-30 TW TW110132143A patent/TW202227080A/zh unknown
- 2021-08-30 EP EP21861757.9A patent/EP4218764A4/en active Pending
-
2023
- 2023-02-24 US US18/113,887 patent/US20230241062A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sprenger et al. | Management of motor and non-motor symptoms in Parkinson’s disease | |
| JP6889231B2 (ja) | レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法 | |
| Nyholm | Pharmacokinetic optimisation in the treatment of Parkinson’s disease: an update | |
| Di Stefano et al. | New drug delivery strategies for improved Parkinson's disease therapy | |
| Di Luca et al. | Newly approved and investigational drugs for motor symptom control in Parkinson's disease | |
| JP2023552700A5 (https=) | ||
| Khan | Off spells and dyskinesias: pharmacologic management of motor complications | |
| JP6196704B2 (ja) | 神経因性疾病の治療のための医薬 | |
| RU2019111096A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| KR20230118933A (ko) | 초기 특발성 파킨슨병에 대한 치료 요법 | |
| Alotaibi et al. | Parkinson's disease: current treatment modalities and emerging therapies | |
| JP2009506978A5 (https=) | ||
| JP2023546140A5 (https=) | ||
| JPWO2022045336A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| Moore et al. | Management of Motor | |
| CN101797243B (zh) | 一种含有左旋多巴和冰片的组合物及其应用 | |
| Obering et al. | Update on apomorphine for the rapid treatment of hypomobility (“off”) episodes in Parkinson's disease | |
| JP7485874B2 (ja) | 神経変性障害の治療のための医薬組成物の連続的投与 | |
| Todorova et al. | Subcutaneous, intranasaland transdermal dopamine agonists in the management of Parkinson’s disease | |
| Antonini | New strategies in motor parkinsonism | |
| JP2016503406A5 (https=) | ||
| Karabin et al. | The recent guidelines for pharmacotherapy of Parkinson’s Disease | |
| KR20250150676A (ko) | 당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산 | |
| Reichmann et al. | NEW DEVELOPMENTS FOR PARKINSON’S THERAPY WITH COMT INHIBITORS |